返回 Agenda
Patient-Focused Medicines Development: Where It has Led Us to Today, What Challenges Remain, and What Do We Still Need to Do to Achieve Success?
Session Chair(s)
Lode Dewulf
Patient and Medical Affairs Consultant
Corvalus, Belgium
Using a multi-disciplinary approach, we will take a dynamic look at the experience of those involved in patient engagement, across stakeholder groups representing different regions, to understand how we have collectively moved the needle. As organizations have embarked upon efforts and implemented initiatives, we will provide a bird’s eye view of the impact of patient engagement across various stakeholders.
Learning Objective : Describe how patient engagement has evolved across stakeholder groups in the past few years; Discuss the impact of collective approaches on patient engagement in medicines development lifecycle; Apply key learnings from collective approaches in their own efforts; Describe recent achievements in patient engagement and identify remaining challenges.
Speaker(s)
Panelist
David Gray
Pfizer Inc, United States
Senior Director
Panelist
Sarah Krug, MS
CANCER101, United States
Executive Director
Panelist
Pamela Tenaerts, MD, MBA
Medable, United States
Chief Scientific Officer
Panelist
Lisa Cone
Parkinson's Disease Foundation Initiative, United States
Patient